LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset - HMS LINCS Database

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 32 of 66
Next
>>
>
776 to 800 of 1647 records
per page:

Small Molecule	barcode	cell_count	frac_dead	corpse_count	cell_count_dead	row	column	agent	concentration	role	timepoint	replicate	cell_line	dead_count	fraction_dead	cell_count__time0	dead_count__time0	cell_count__ctrl	dead_count__ctrl	fraction_dead__ctrl	increase_fraction_dead	GRvalue
Etoposide	180619_MC_10	659	0.1323	82	16	4	19	Etoposide	3.193598006	treatment	72	2	MCF10A-GM_2	98	0.1295	635.9	71.1	15071	356.7	0.0231	0.10638	0.0079
Etoposide	180619_MC_10	732	0.1621	113	24	8	20	Etoposide	3.193598006	treatment	72	2	MCF10A-GM_3	137	0.1577	635.9	71.1	15071	356.7	0.0231	0.13458	0.0313
Etoposide	180619_MC_11	756	0.1159	81	16	6	8	Etoposide	3.193598006	treatment	72	2	MCF10A-GM_4	97	0.1137	635.9	71.1	15071	356.7	0.0231	0.09064	0.0386
Etoposide	180619_MC_11	749	0.1092	75	15	14	4	Etoposide	3.193598006	treatment	72	2	MCF10A-GM_5	90	0.1073	635.9	71.1	15071	356.7	0.0231	0.08420	0.0365
Etoposide	180619_MC_11	713	0.1040	66	15	14	17	Etoposide	3.193598006	treatment	72	2	MCF10A-GM_6	81	0.1020	635.9	71.1	15071	356.7	0.0231	0.07894	0.0254
Etoposide	180619_MC_12	710	0.2364	174	35	4	3	Etoposide	3.193598006	treatment	72	2	MCF10A-GM_7	209	0.2274	635.9	71.1	15071	356.7	0.0231	0.20435	0.0244
Etoposide	180619_MC_12	689	0.1871	118	33	8	10	Etoposide	3.193598006	treatment	72	2	MCF10A-GM_8	151	0.1798	635.9	71.1	15071	356.7	0.0231	0.15669	0.0177
Etoposide	180619_MC_12	639	0.1997	122	30	12	4	Etoposide	3.193598006	treatment	72	2	MCF10A-GM_9	152	0.1922	635.9	71.1	15071	356.7	0.0231	0.16909	0.0011
Etoposide	180619_MC_10	754	0.0971	60	19	4	15	Etoposide	9.98	treatment	72	2	MCF10A-GM_1	79	0.0948	635.9	71.1	15071	356.7	0.0231	0.07176	0.0380
Etoposide	180619_MC_10	708	0.1110	58	27	6	22	Etoposide	9.98	treatment	72	2	MCF10A-GM_2	85	0.1072	635.9	71.1	15071	356.7	0.0231	0.08411	0.0238
Etoposide	180619_MC_10	765	0.1130	49	43	10	7	Etoposide	9.98	treatment	72	2	MCF10A-GM_3	92	0.1074	635.9	71.1	15071	356.7	0.0231	0.08428	0.0413
Etoposide	180619_MC_11	723	0.1418	95	21	4	13	Etoposide	9.98	treatment	72	2	MCF10A-GM_4	116	0.1383	635.9	71.1	15071	356.7	0.0231	0.11519	0.0285
Etoposide	180619_MC_11	749	0.2275	183	29	7	17	Etoposide	9.98	treatment	72	2	MCF10A-GM_5	212	0.2206	635.9	71.1	15071	356.7	0.0231	0.19753	0.0365
Etoposide	180619_MC_11	811	0.0964	71	14	14	16	Etoposide	9.98	treatment	72	2	MCF10A-GM_6	85	0.0949	635.9	71.1	15071	356.7	0.0231	0.07179	0.0547
Etoposide	180619_MC_12	811	0.2629	178	82	9	8	Etoposide	9.98	treatment	72	2	MCF10A-GM_6	260	0.2428	635.9	71.1	15071	356.7	0.0231	0.21969	0.0547
Etoposide	180619_MC_12	767	0.2744	184	77	13	7	Etoposide	9.98	treatment	72	2	MCF10A-GM_7	261	0.2539	635.9	71.1	15071	356.7	0.0231	0.23082	0.0419
Etoposide	180619_MC_12	760	0.1966	120	53	13	12	Etoposide	9.98	treatment	72	2	MCF10A-GM_8	173	0.1854	635.9	71.1	15071	356.7	0.0231	0.16235	0.0398
Neratinib	180619_MC_10	15121	0.0272	62	351	3	13	Neratinib	0.001081167	treatment	72	2	MCF10A-GM_1	413	0.0266	635.9	71.1	15071	356.7	0.0231	0.00351	1.0014
Neratinib	180619_MC_10	14803	0.0178	51	213	8	22	Neratinib	0.001081167	treatment	72	2	MCF10A-GM_2	264	0.0175	635.9	71.1	15071	356.7	0.0231	-0.00555	0.9922
Neratinib	180619_MC_10	15146	0.0210	53	266	11	17	Neratinib	0.001081167	treatment	72	2	MCF10A-GM_3	319	0.0206	635.9	71.1	15071	356.7	0.0231	-0.00245	1.0022
Neratinib	180619_MC_11	14858	0.0227	79	260	3	17	Neratinib	0.001081167	treatment	72	2	MCF10A-GM_4	339	0.0223	635.9	71.1	15071	356.7	0.0231	-0.00077	0.9938
Neratinib	180619_MC_11	15178	0.0173	46	217	14	10	Neratinib	0.001081167	treatment	72	2	MCF10A-GM_5	263	0.0170	635.9	71.1	15071	356.7	0.0231	-0.00604	1.0031
Neratinib	180619_MC_11	14103	0.0208	39	255	14	11	Neratinib	0.001081167	treatment	72	2	MCF10A-GM_6	294	0.0204	635.9	71.1	15071	356.7	0.0231	-0.00265	0.9711
Neratinib	180619_MC_12	14979	0.0228	90	253	4	5	Neratinib	0.001081167	treatment	72	2	MCF10A-GM_7	343	0.0224	635.9	71.1	15071	356.7	0.0231	-0.00069	0.9973
Neratinib	180619_MC_12	14972	0.0200	85	216	11	22	Neratinib	0.001081167	treatment	72	2	MCF10A-GM_8	301	0.0197	635.9	71.1	15071	356.7	0.0231	-0.00337	0.9971

|<
<<
Previous
Page 32 of 66
Next
>>
>
776 to 800 of 1647 records
per page:

HMS LINCS Project

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)